Brought to you by 
Teva licenses Active Biotech's laquinimod; Active later regains rights
25 Feb 2019
Executive Summary
Israeli-based Teva Pharmaceutical Industries Ltd. has been granted the exclusive worldwide rights to develop, manufacture, and market Active Biotech AB's (autoimmune and inflammatory diseases and cancer) laquinimod, an immunomodulatory drug candidate for multiple sclerosis. Active Biotech is keeping rights to the Nordic countries and Baltic states of Lithuania, Latvia, and Estonia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva licenses Active Biotech's laquinimod; Active later regains rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice